NDA 217686 · Idorsia
Tryvio
Aprocitentan · Oral · Endothelin Receptor Antagonist
NovelCDER novel approval, Mar 19, 2024: To treat hypertension
Last checked: Nov 19, 2026Latest source record: Aug 6, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Mar 19, 2024
Approved uses
1
Original approval plus efficacy supplements
Registered trials
14
3 Phase 3, 0 recruiting
FAERS reports
22
13 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: EMBRYO-FETAL TOXICITY TRYVIO is contraindicated for use during pregnancy because it may cause fetal harm if used by pregnant patients. Therefore in patients who can become pregnant, exclude pregnancy prior to initiation of TRYVIO. Advise use of effective contraception before the start of TRYVIO, during treatment and for one month after stopping treatment. When pregnancy is detected, discontinue TRYVIO as soon as possible [see Dosage and Administration (2.2) , Contraindications (4.1) , Warnings and Precautions (5.1) , Use in Specific Populations (8.1) ] . WARNING: EMBRYO–FETAL TOXICITY See full prescribing information for complete boxed warning. Based on animal data TRYVIO may cause fetal harm if used by pregnant patients and is contraindicated in pregnancy. ( 4.1 , 5.1 , 8.1 ) For patients who can become pregnant, exclude pregnancy prior to initiation of treatment with TRYVIO....
What it is approved for
From the label in effect Aug 14, 2026.
TRYVIO, in combination with other antihypertensive drugs, is indicated for the treatment of hypertension, to lower blood pressure (BP) in adult patients who are not adequately controlled on other drugs. Lowering BP reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. There are no controlled trials demonstrating reduction of risk of these events with TRYVIO. Control of high BP should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve BP goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is BP reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher BPs, so...
Mechanism: Aprocitentan is an ERA that inhibits the binding of endothelin (ET)-1 to ET A and ET B receptors. ET-1, via its receptors (ET A and ET B ), mediates a variety of deleterious effects such as vasoconstriction, fibrosis, cell proliferation, and inflammation. In hypertension, ET-1 can cause endothelial dysfunction, vascular hypertrophy and remodeling, sympathetic activation, and increased aldosterone synthesis.
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 19, 2024 Original approval · Type 1 - New Molecular Entity NovelLabelMedication GuideLetter
1 products under this application
- TRYVIO · APROCITENTAN 12.5MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Aprocitentan" as an intervention, any sponsor and status, largest first.
- Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential HypertensionPivotal-lookingCompleted
Idorsia Pharmaceuticals Ltd.Industry
NCT02603809 · 1,659 participants · Start Dec 14, 2015 · Primary completion Feb 28, 2017
Drug: Aprocitentan 5 mg; Aprocitentan 10 mg and 4 more · For: Essential Hypertension
Sites: Fort Payne, Alabama; Chandler, Arizona; Peoria, Arizona · 90 sites in all
- A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its SafetyPivotal-lookingCompleted
Idorsia Pharmaceuticals Ltd.Industry
NCT03541174 · 730 participants · Start Jun 18, 2018 · Primary completion May 14, 2021
Drug: Aprocitentan 12.5 mg; Aprocitentan 25 mg and 1 more · For: Resistant Hypertension
Sites: Alexander City, Alabama; Inglewood, California; Lincoln, California · 159 sites in all
- A Study Evaluating Aprocitentan Tablets(SYH9108) for the Treatment of Resistant HypertensionPivotal-lookingNot yet recruiting
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Industry
NCT07635914 · 382 participants (planned) · Start May 31, 2026 · Primary completion Dec 28, 2029
Drug: Aprocitentan tablets(SYH9108); Placebo · For: Resistant Hypertension
- To Study the Effect of Aprocitentan on the Electrical Activity of the Heart in Healthy Men and WomenCompleted
Idorsia Pharmaceuticals Ltd.Industry
NCT04281342 · 48 participants · Start Jan 14, 2020 · Primary completion Aug 3, 2021
Drug: Aprocitentan 25 mg; Aprocitentan 100 mg and 1 more · For: Healthy Subjects
Sites: Mannheim, Germany
Idorsia Pharmaceuticals Ltd.Industry
NCT05196399 · 36 participants · Start Feb 2, 2022 · Primary completion Mar 27, 2022
Drug: Aprocitentan (Formulation A); Aprocitentan (Formulation B) · For: Healthy Subjects
Sites: Pilsen, Czechia
Idorsia Pharmaceuticals Ltd.Industry
NCT02708004 · 24 participants · Start Jun 1, 2016 · Primary completion Dec 1, 2016
Drug: Aprocitentan · For: Healthy Subjects
Sites: Lausanne, Switzerland
Idorsia Pharmaceuticals Ltd.Industry
NCT03245229 · 20 participants · Start Aug 10, 2017 · Primary completion Sep 18, 2017
Drug: Aprocitentan; Rosuvastatin · For: Healthy Subjects
Sites: Pilsen, Czechia
Idorsia Pharmaceuticals Ltd.Industry
NCT03586570 · 20 participants · Start Jul 17, 2018 · Primary completion Sep 10, 2018
Drug: Aprocitentan 25mg; Placebo · For: Healthy Subjects
Sites: Anaheim, California
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea3
- malaise3
- heart rate increased2
- oedema peripheral2
- peripheral swelling2
- weight increased2
- abdominal discomfort1
- anaemia1
- aortic valve replacement1
- arthralgia1
- asthenia1
- atrial fibrillation1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2021 | 1 |
| 2025 | 11 |
| 2026 | 10 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial.
Schlaich MP, Bellet M, Weber MA, et al. · Lancet 2022 · Randomized Controlled Trial, Multicenter Study
- Aprocitentan in Patients With Chronic Kidney Disease and Resistant Hypertension.
Rossignol P, Clozel M, Dreier RF, et al. · Hypertension 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- Aprocitentan for Blood Pressure Reduction in Black Patients.
Flack JM, Schlaich MP, Weber MA, et al. · Hypertension 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Identifying and treating resistant hypertension in PRECISION: A randomized long-term clinical trial with aprocitentan.
Danaietash P, Verweij P, Wang JG, et al. · J Clin Hypertens (Greenwich) 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Effects of aprocitentan on prognostically relevant ambulatory blood pressure-derived variables in resistant hypertension.
Schlaich MP, Weber MA, Flack JM, et al. · J Hypertens 2026 · Clinical Trial, Phase III, Randomized Controlled Trial
- Efficacy and Safety of Aprocitentan in the Treatment of Hypertension: A Meta-Analysis of Evidence from Randomized Controlled Trials.
Zheng L, Liu M, Gu X, et al. · Rev Cardiovasc Med 2025 · Systematic Review
Sponsor: Idorsia
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.